

### REMARKS

The presently pending claims of the application are claims 1-4, 7-14, 17-18 and 23-29. Claims 4, 9, 10, 13 and 14 have been amended to remove multiple dependencies. Claims 28 and 29 have been added. These claims find support in originally filed claim 4. Claims 5, 6, 15, 16, 19, 20, 21, 23 are canceled. No new matter is added.

Attached hereto is a marked-up[ version of the changes made to the claims by the current preliminary amendment. The attached page is captioned **"Version with markings to show changes made."**


Applicants respectfully submit that the application is in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue.

If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned at (650) 327-3400.

In the event that the transmittal letter is separated from this document and the Patent Office determines that extensions or other relief is required and/or fees are due applicants, Applicants petition for any required relief, including extensions of time, and authorize the Commissioner to charge our Deposit Account No. 50-0815 for any fees due in connection with the filing of this document. The Patent Office is not authorized to charge issue fees to our Deposit Account.

Respectfully submitted,  
Bozicevic, Field and Francis LLP

Date: June 25, 2001

  
\_\_\_\_\_  
Pamela J. Sherwood, Ph.D.  
Reg. No. 36,677

200 Middlefield Road, Suite 200  
Menlo Park, California 94025  
(650) 327-3400 (P)  
(650) 327-3231 (F)

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**Claims 4, 9, 10, 13 and 14 have been amended as follows:**

4. (amended) The method according to [any one of claims 1 to 2] claim 1 wherein said compound is able to modulate interaction between ATM and p53.

9. (amended) A peptide according to claim 7 [or claim 8] capable of modulating interaction between ATM and p53.

10. (amended) A nucleic acid isolate encoding a peptide according to [any of claims 7 to 9] claim 7.

13. (amended) The peptide of claim 11 [or claim 12] capable of modulating interaction between ATM and p53.

14. (amended) A nucleic acid isolate encoding a peptide according to [any one of claim 11 to 13] claim 11.

**Claims 5, 6, 15, 16, 19, 20, 21 and 23 have been cancelled.**

**The Following Claims 28 and 29 have been added:**

28. (New) The method according to claim 2, wherein said compound is able to modulate interaction between ATM and p53.

29. (New) The method according to claim 3, wherein said compound is able to modulate interaction between ATM and p53.